RSV
20
7
9
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 20 trials
100.0%
+13.5% vs benchmark
20%
4 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (20)
Immune Reponses to RSV B Challenge in Older Adults (A Controlled Human Infection Study With RSV in Older People-02)
A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
The Role of Vitamin D and Vitamin D Receptor in Recurrent Wheezing in Children With Bronchiolitis: Immunological Association With T-lymphocyte Mitochondrial Mass
Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy
Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults
RSV Vaccination to Reduce Recurrent AECOPD
Clinical Evaluation of the VitaSIRO Solo™ Respiratory Assay
Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine
Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
Covid Flu A/B and RSV 4 in 1 Diagnostic Test
RSV Burden in Hong Kong
Preparedness Through Respiratory Virus Epidemiology and Community Engagement
Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings
SURVEILLANCE, ASSESSMENT AND DETECTION OF INFLUENZA ASSOCIATED RESPIRATORY INFECTIONS IN HIV POSITIVE AND NEGATIVE INDIVIDUALS IN LUSAKA, ZAMBIA
A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients
Effectiveness And Impact Of Nirsevimab In Chile (NIRSE-CL)
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age
Adherence to Palivizumab Prophylaxis
The Impact of a Short Intervention During RSV Prophylaxis on Influenza Vaccination Rate.